Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25729639 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL17808690 | 0.96 | CES2 (0.44) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL22024176 | 0.90 | KDM4E (0.39) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL22932423 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL20128726 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL26849925 | 0.83 | CES2 (0.53) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL27408407 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL4402902 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL20133152 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1CES2MEN1KMT2A | |
| SCHEMBL20223175 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | KDM4E 1254/4885ALDH1A1 4031/4885CES2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.